Published On: Wed, Oct 19th, 2016

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Latest Broker Views


A number of investment brokers have recently updated their price targets on shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Most recent broker ratings

10/11/2016 – Momenta Pharmaceuticals, Inc. was upgraded to “overweight” by analysts at Barclays. They now have a USD 19 price target on the stock.

09/07/2016 – Momenta Pharmaceuticals, Inc. was downgraded to “sell” by analysts at Maxim Group. They now have a USD 6 price target on the stock.

06/06/2016 – Goldman Sachs began new coverage on Momenta Pharmaceuticals, Inc. giving the company a “neutral” rating. They now have a USD 14 price target on the stock.

05/04/2016 – Momenta Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 18 price target on the stock.

02/19/2016 – Momenta Pharmaceuticals, Inc. had its “sell” rating reiterated by analysts at UBS. They now have a USD 9 price target on the stock.

02/19/2016 – Momenta Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 21 price target on the stock.

02/19/2016 – Momenta Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Brean Capital. They now have a USD 19 price target on the stock.

02/18/2016 – Momenta Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 20 price target on the stock.

11/09/2015 – Momenta Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at Cowen. They now have a USD 20 price target on the stock.

08/19/2015 – Momenta Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Sanford C. Bernstein. They now have a USD 31 price target on the stock.

03/30/2015 – Momenta Pharmaceuticals, Inc. had its “sell” rating reiterated by analysts at Zacks.

01/22/2015 – Momenta Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Bank of America Merrill Lynch. They now have a USD 14 price target on the stock.

05/07/2014 – Momenta Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 17 price target on the stock.

03/05/2014 – Momenta Pharmaceuticals, Inc. was downgraded to “sell” by analysts at TheStreet.

10/14/2013 – R. F. Lafferty began new coverage on Momenta Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 19 price target on the stock.

The share price of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was up +0.67% during the last day of trading, with a day high of 12.31. 372086 shares were traded during the last session.

The stock’s 50 day moving average is 11.90 and its 200 day moving average is 11.13. The stock’s market capitalization is 823.16M. Momenta Pharmaceuticals, Inc. has a 52-week low of 7.86 and a 52-week high of 18.85.

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.